A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. Korsana Biosciences has catapulted out of stealth with $175 million and designs for a 2027 clinical debut.
The newly disclosed funds consist of a $25 million seed round from 2024, when Korsana was founded, and a $150 million series A led by Wellington Management and TCGX alongside others like J.P. Morgan Life Sciences Private Capital, Sanofi Ventures and Foresite Capital, according to a Feb. 18 release.